This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Hang on a second…

This CME Activity has expired and is no longer available for credit.

Current Management of Hereditary Angioedema: On-Demand Case Series

Current Management of Hereditary Angioedema: On-Demand Case Series



Time to Complete

1 hour


December 6, 2017


December 6, 2018
Add to Queue

Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Accredited Provider

Provided by Integrity Continuing Education, Inc.

Commercial Supporter

Supported by an educational grant from Pharming Healthcare, Inc.

Program Description

Hereditary angioedema (HAE) is a rare, potentially life-threatening disease caused by deficiency or dysfunction of C1 esterase inhibitor (C1-INH), a part of the complement system involved in inhibition of swelling. Many of those most commonly reported symptoms of HAE (abdominal pain and swelling, swelling of extremities, and throat closure) overlap with conditions such as anaphylaxis, gastrointestinal disorders, acute surgical conditions, or acute pain conditions, making recognition of HAE very challenging. This, in turn, often leads to delays in diagnosis as well as inappropriate treatment. This program will utilize a case-based format to engage healthcare providers by linking discussion of the latest scientific data with its application in the clinical setting.

Intended Audience

This educational initiative has been designed for allergists, emergency medicine physicians, nurse practitioners (NPs), and physician assistants (PAs) in specialty practice who are involved in the diagnosis and management of patients with HAE.

Educational Objectives

Upon completion of this educational activity, participants should be able to:

  • Differentiate key signs and symptoms of HAE from other common conditions and review the diagnostic tests in HAE
  • Identify key considerations in development of individualized treatment plans for patients with HAE

Conflict Of Interest Disclosure Policy

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent COI they may have as related to the content of this activity. All identified COI are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Faculty/planners reported their financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity under the Faculty heading below.


Joshua S. Jacobs, MD
Medical Director of Clinical Research
Allergy & Asthma Medical Group
Walnut Creek, CA

Dr. Jacobs discloses the following:
Consultant/Advisor: CSL Behring, Pharming, Regeneron, Shire, Teva
Contracted Research: CSL Behring, Genentech, Regeneron, Sanofi, Shire, Teva
Speaker: Shire, Teva

Accredited Provider Disclosure

Patima Tanapat, PhD, has no real or apparent conflicts of interest to disclose.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

Designation Statement

Integrity Continuing Education designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM  . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Pharming Healthcare, Inc. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education, Inc. and Pharming Healthcare, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.


There are no fees for participating and receiving CME credit for this activity. During the period of December 6, 2017 through December 6, 2018, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pre-test
  • Study the educational activity
  • Complete the post-test and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70%.

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or

If you have any questions relating to your certificate or other issues with this activity, please contact

Privacy Policy


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue